Introduction/Background Endometrial cancer is one the most common female cancers, a better stratification into high- or low-risk is mandatory to identified patients who might benefit of a tailored adjuvant therapy. Recent studies have demonstrated that a new biomarkers panel, assessed immunohistochemically, could be helpful in a better prognosis prediction and thus in patients selection.
Methodology This is a retrospective analysis of the following Immunohistochemical markers: L1 Cell Adhesion Molecule (L1CAM), p53, β-catenin, Ki67, Estrogen receptor (ER) and Progesterone receptor (PR) in patients with diagnosis of endometrial cancer.
Results We analyzed twenty-one patients with a median age of 58 years (range, 34–88 years). Final histology was endometrioid in 14 (66,6%) cases, clear cell in 1 (4,8%) case, serous in 5 (23,8%) cases, mixed in 1 (4,8%) case. Seven (33%) patients were L1CAM positive (cut off value 10%). L1CAM expression was associated with advanced age (74 years vs 67 years), non-endometrioid morphology and loss of ER and PR expression. An important association was found with p53-mutant tumors often showing diffuse L1CAM expression, mostly in the non-endometrioid subtype. Out of a total of 14 endometrioid endometrial cancer, only one was found to be p53 mutant positive and 13 p53 wild-type (wt) positive. All non-endometrioid EC expressed p53 wt and L1CAM markers and 4/5 (80%) shows a L1CAM positivity >75%. None association was found between L1CAM and Ki67 expression and depth of myometrial invasion, histologic grade, lymph vascular space invasion and metastatic node. Endometrioid and non-endometrioid subtype demonstrated diffuse β-catenin staining >50%.
Conclusion In agreement with the literature, these data confirmed that in high risk endometrial cancer patients L1CAM and p53 expression is more frequent. A high association was found between L1CAM expression and mutant p53 expression in the non-endometrioid subtype endometrial cancer.
Disclosure Nothing to disclose.
Statistics from Altmetric.com
If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.